Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda To Hunt For New CNS Therapeutics With Heptares' Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

Making G-Protein coupled receptors in the CNS drugable is the aim of a research collaboration between Takeda and U.K. biotech, Heptares Therapeutics.

You may also be interested in...

Deals Of The Week: Sun/Dusa; Pfizer/Alliance For Lupus Research; Merck/Regenstrief Institute

Preclinical protein platform play Envoy got taken out by Takeda last week for up to $140 million. That magical “up to” typically hides a multitude of sins, but here that may not be the case.

Shire Exercises Option On Heptares' Preclinical Candidate In $190 Million Deal

The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.

U.K's Heptares Signs Up AstraZeneca In Latest GPCR-Focused Discovery Pact

AstraZeneca becomes the third Big Pharma in six weeks to sign up for U.K-based Heptares' GPCR stabilizing technology.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts